Cargando…

Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor

While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HI...

Descripción completa

Detalles Bibliográficos
Autores principales: Emert-Sedlak, Lori A., Shi, Haibin, Tice, Colin M., Chen, Li, Alvarado, John J., Shu, Sherry T., Du, Shoucheng, Thomas, Catherine E., Wrobel, Jay E., Reitz, Allen B., Smithgall, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503669/
https://www.ncbi.nlm.nih.gov/pubmed/36146831
http://dx.doi.org/10.3390/v14092025
_version_ 1784796022974709760
author Emert-Sedlak, Lori A.
Shi, Haibin
Tice, Colin M.
Chen, Li
Alvarado, John J.
Shu, Sherry T.
Du, Shoucheng
Thomas, Catherine E.
Wrobel, Jay E.
Reitz, Allen B.
Smithgall, Thomas E.
author_facet Emert-Sedlak, Lori A.
Shi, Haibin
Tice, Colin M.
Chen, Li
Alvarado, John J.
Shu, Sherry T.
Du, Shoucheng
Thomas, Catherine E.
Wrobel, Jay E.
Reitz, Allen B.
Smithgall, Thomas E.
author_sort Emert-Sedlak, Lori A.
collection PubMed
description While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HIV-1 infection is therefore an essential goal of current AIDS research. This review is focused on the discovery of pharmacological inhibitors of the HIV-1 Nef accessory protein. Nef is well known to enhance HIV-1 infectivity and replication, and to promote immune escape of HIV-infected cells by preventing cell surface MHC-I display of HIV-1 antigens. Recent progress shows that Nef inhibitors not only suppress HIV-1 replication, but also restore sufficient MHC-I to the surface of infected cells to trigger a cytotoxic T lymphocyte response. Combining Nef inhibitors with latency reversal agents and therapeutic vaccines may provide a path to clearance of viral reservoirs.
format Online
Article
Text
id pubmed-9503669
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95036692022-09-24 Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor Emert-Sedlak, Lori A. Shi, Haibin Tice, Colin M. Chen, Li Alvarado, John J. Shu, Sherry T. Du, Shoucheng Thomas, Catherine E. Wrobel, Jay E. Reitz, Allen B. Smithgall, Thomas E. Viruses Review While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HIV-1 infection is therefore an essential goal of current AIDS research. This review is focused on the discovery of pharmacological inhibitors of the HIV-1 Nef accessory protein. Nef is well known to enhance HIV-1 infectivity and replication, and to promote immune escape of HIV-infected cells by preventing cell surface MHC-I display of HIV-1 antigens. Recent progress shows that Nef inhibitors not only suppress HIV-1 replication, but also restore sufficient MHC-I to the surface of infected cells to trigger a cytotoxic T lymphocyte response. Combining Nef inhibitors with latency reversal agents and therapeutic vaccines may provide a path to clearance of viral reservoirs. MDPI 2022-09-13 /pmc/articles/PMC9503669/ /pubmed/36146831 http://dx.doi.org/10.3390/v14092025 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Emert-Sedlak, Lori A.
Shi, Haibin
Tice, Colin M.
Chen, Li
Alvarado, John J.
Shu, Sherry T.
Du, Shoucheng
Thomas, Catherine E.
Wrobel, Jay E.
Reitz, Allen B.
Smithgall, Thomas E.
Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor
title Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor
title_full Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor
title_fullStr Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor
title_full_unstemmed Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor
title_short Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor
title_sort antiretroviral drug discovery targeting the hiv-1 nef virulence factor
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503669/
https://www.ncbi.nlm.nih.gov/pubmed/36146831
http://dx.doi.org/10.3390/v14092025
work_keys_str_mv AT emertsedlakloria antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor
AT shihaibin antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor
AT ticecolinm antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor
AT chenli antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor
AT alvaradojohnj antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor
AT shusherryt antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor
AT dushoucheng antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor
AT thomascatherinee antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor
AT wrobeljaye antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor
AT reitzallenb antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor
AT smithgallthomase antiretroviraldrugdiscoverytargetingthehiv1nefvirulencefactor